Saturday, October 3, 2026

KLA Forecasts Mid-to-High Teens Growth in Advanced Packaging as Global AI Chip Race Drives Equipment Orders

KLA Corporation projects mid-to-high teens percentage growth for its advanced packaging segment in calendar 2026, outpacing traditional semiconductor equipment sales. The shift reflects accelerating global investment in 2.5D and 3D chip stacking technologies required for AI processors, with TSMC's Taiwan facilities, Intel's US operations, and Samsung's Korean plants all expanding capacity.

KLA Forecasts Mid-to-High Teens Growth in Advanced Packaging as Global AI Chip Race Drives Equipment Orders
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

KLA Corporation expects mid-to-high teens percentage growth in its advanced packaging business for calendar 2026, driven by global demand for AI chip manufacturing equipment. The company's packaging segment is outperforming traditional semiconductor equipment sales as chipmakers worldwide respond to AI accelerator requirements.

Advanced packaging technologies—2.5D and 3D chip stacking—connect multiple chips in a single package to achieve higher performance and power efficiency. These methods bypass traditional scaling limitations and require specialized inspection and metrology systems that KLA supplies to manufacturers across Asia, North America, and Europe.

The global race to secure advanced packaging capacity has intensified over 18 months. TSMC's CoWoS (Chip-on-Wafer-on-Substrate) facilities in Taiwan remain supply-constrained due to orders from Nvidia and AMD. Intel's Foveros technology targets US-based production, while Samsung's X-Cube capabilities serve Korean and international clients.

Lumentum Holdings reported over 65% year-over-year revenue growth in its latest quarter, projecting quarterly revenue above $750 million next quarter. This indicates demand extends beyond inspection equipment to optical components used in packaging manufacturing worldwide.

The growth rates suggest packaging equipment capital expenditures are accelerating faster than front-end semiconductor fabrication spending globally. Traditional chip manufacturing faces cyclical headwinds, while advanced packaging investments maintain momentum tied to AI deployment schedules across data centers in the US, Europe, and Asia.

Equipment suppliers with advanced packaging exposure present opportunities for international investors. KLA's outlook and Lumentum's results indicate strong 2026 revenue visibility despite broader semiconductor uncertainty. Investors should monitor order rates from packaging specialists like Kulicke & Soffa and ASM Pacific Technology as leading indicators.

Advanced packaging represents a structural shift rather than cyclical upturn. AI accelerators require bandwidth and thermal performance that traditional packaging cannot deliver—a fundamental requirement that should sustain global equipment demand independent of near-term inventory cycles.


Sources:
1 Globe Newswire, "Olympians Inspire Expands School Assembly and Leadership Workshop Programming Featuring Elite Athlet" (March 23, 2026)
2 Globe Newswire, "Willis partners with Circle Asia to launch Asia’s first insurance facility for collectors and galler" (March 23, 2026)
3 Yahoo Finance, "Marvell Technology Inc. (MRVL) Unveils Advanced Switch for AI Data Center Scale-Up Infrastructure" (March 22, 2026)
4 Yahoo Finance, "Is It Too Late To Consider Lumentum Holdings (LITE) After An 83% Year To Date Surge?" (March 21, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com